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ABSTRACT  35 
BACKGROUND: Neutrophils and IL-17A have been linked mechanistically in models of allergic 36 
airways disease and have been associated with asthma severity. However, their role in paediatric 37 
asthma is unknown.  38 
OBJECTIVES: To investigate the role of neutrophils and the IL-17A pathway in mediating paediatric 39 
severe therapy resistant asthma (STRA). 40 
METHODS: Children with STRA (n=51, age 12.6 (6 -16.3) years) and non-asthmatic controls (n=15, 41 
age 4.75 (1.6-16) years) underwent clinically indicated fiberoptic bronchoscopy, bronchoalveolar 42 
lavage (BAL), endobronchial brushings and biopsy. Neutrophils, IL-17A and IL-17RA expressing cells 43 
and levels of IL-17A and IL-22 were quantified in BAL and biopsies and related to clinical features. 44 
Primary bronchial epithelial cells (PBECs) were stimulated with IL-17A and/or IL-22, with and without 45 
Budesonide. 46 
RESULTS: Children with STRA had increased intra-epithelial neutrophils, which positively correlated 47 
with FEV1 %predicted (r=0.43, p=0.008). Neutrophil-high patients also had better symptom control, 48 
despite lower dose maintenance inhaled steroids. Submucosal neutrophils were not increased in 49 
STRA. Submucosal and epithelial IL-17A positive cells and BAL IL-17A and IL-22 levels were similar in 50 
STRA and controls. However, there were significantly more IL-17RA positive cells in the submucosa 51 
and epithelium in children with STRA compared to controls (p=0.001).  Stimulation of PBECs with IL-52 
17A enhanced mRNA expression of IL-17RA and increased release of IL-8, even in the presence of 53 
Budesonide. 54 
CONCLUSIONS: A proportion of children with STRA exhibit increased intra-epithelial airway 55 
neutrophilia that correlated with better lung function. STRA was additionally characterised by 56 
increased airway IL-17RA expression. These data suggest a potential beneficial rather than adverse 57 
role for neutrophils in paediatric severe asthma pathophysiology.  58 
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Word count: 247 59 
 60 
ABBREVIATIONS 61 
ACT asthma control test 62 
ASM airway smooth muscle 63 
BAL bronchoalveolar lavage 64 
BEGM bronchial epithelial growth medium 65 
BMI body mass index 66 
ECM extracellular matrix  67 
ELISA enzyme-linked immunosorbent assay 68 
FEV1 Forced expiratory volume in 1 second  69 
GR glucocorticoid receptor 70 
HBE human bronchial epithelium 71 
PBEC primary bronchial epithelial cell 72 
FMO fluorescence minus one 73 
PBMC peripheral blood mononuclear cells 74 
PCR polymerase chain reaction 75 
RBM reticular basement membrane  76 
STRA severe therapy resistant asthma 77 
  78 
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INTRODUCTION 79 
Severe asthma is heterogeneous and can be divided into sub-phenotypes (1-3). Severe therapy 80 
resistant asthma (STRA) affects a small proportion of children with asthma and is characterised by 81 
persistent symptoms, acute severe exacerbations and/or fixed airflow obstruction despite treatment 82 
with high-dose steroid therapy, and after modifiable factors such as poor adherence and persistent 83 
allergen exposure have been addressed (4). Since Th2 mediated eosinophilic asthma generally 84 
responds well to steroid treatment, the lack of responsiveness to steroids in STRA suggests an 85 
alternative inflammatory pathway in these children. We have previously shown that children with 86 
STRA exhibit airway eosinophilia and remodelling, but a paucity of classical Th2 cytokines (IL-4, -5 87 
and -13) (5).  88 
In adults, airway neutrophils have been associated with increased asthma severity (1, 6, 7) but their 89 
functional role in mediating disease pathophysiology is unclear. Elevated levels of IL-17A have been 90 
reported in sputum, bronchoalveolar lavage (BAL) fluid and peripheral blood (8-11) in severe 91 
asthmatics and have been implicated in pathogenesis (10, 12). In contrast, little is known about the 92 
role of neutrophils and the IL-17 pathway in children with STRA. IL-17A can induce bronchial 93 
epithelial secretion of pro-inflammatory cytokines including the neutrophil chemoattractants GRO 94 
and IL-8. It is proposed that IL-17A can therefore induce neutrophilic airway inflammation and 95 
promote steroid resistance in severe adult asthma (13). Moreover, IL-17A may also be involved in 96 
airway remodelling. IL-17A has been reported to increase airway smooth muscle (ASM) contraction 97 
upon methacholine stimulation and drive migration of ASM cells in murine models of allergic 98 
inflammation and in asthmatic patients (9, 14, 15). IL-17A binds to the receptor subunits IL-17RA and 99 
C which are expressed on epithelial and mesenchymal cells as well as on some immune cell 100 
populations such as lymphocytes, dendritic cells and monocytes/macrophages in the lung (16). Mice 101 
that lack IL-17RA produce less CXCL1 and CXCL2 upon pulmonary challenge with Klebsiella 102 
pneumoniae (17) and IL-17RA signalling is also necessary for host defence against Candida albicans 103 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
(18). In two mouse models, blocking IL-17R and IL-17RB reduced airway inflammation and airway 104 
hyperreactivity (14). Th17 cells also secrete IL-22, and IL-22 mRNA is elevated in PBMCs in paediatric 105 
severe asthma, and rhinitis (19). Although IL-22 has been described as a pro-inflammatory cytokine 106 
causing airway hyperreactivity in mice and remodelling in both epithelial and airway smooth muscle 107 
cells in humans, it has also been shown to reduce inflammation by supressing cytokine production 108 
from epithelial cells. Taken together, data suggests IL-22 plays different roles in various phases of 109 
airway inflammation (20, 21). 110 
We have previously reported that there was no increase in mucosal or BAL neutrophils in STRA. 111 
However, when re-examining biopsy slides, we noted that some but not all of these children had 112 
intra-epithelial neutrophils. We therefore hypothesised that intra-epithelial neutrophils, together 113 
with elevated IL-17A and IL-22, would be associated with worse asthma severity. We determined the 114 
extent of neutrophilic inflammation in a new cohort of children with STRA and investigated IL-17A 115 
and IL-22 levels and their cellular sources in BAL. We assessed the response of bronchial epithelial 116 
cells to IL-17A, IL-22 and steroids in STRA compared to controls. The findings were then related to 117 
key clinical features and airway remodelling and were confirmed in archived biopsies from an older 118 
cohort of children with STRA to look specifically at intra-epithelial neutrophils which have not 119 
previously been reported.   120 
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PATIENTS, MATERIAL AND METHODS 121 
Subjects 122 
Fifty-one school-aged children with STRA (22) (age 12.6 (6 -16.3) years) were recruited from the 123 
Royal Brompton Hospital. They underwent detailed clinical assessments including spirometry, 124 
exhaled nitric oxide measurements and symptom scores followed by a clinically indicated 125 
bronchoscopy, endobronchial brushings, BAL and endobronchial biopsies to characterize airway 126 
pathology and develop customised treatment plans (4). All children had previously undergone a 127 
detailed assessment to ensure any modifiable factors such as poor adherence or persistent allergen 128 
exposure had been addressed prior to the bronchoscopy (23). Atopy was defined as at least 1 129 
positive serum IgE (sIgE) RAST result (≥0.35 kUI/L) to aeroallergens (HDM, cat, dog, and grass pollen) 130 
and quantified as the sum of sIgE levels of these aeroallergens. 15 non-asthmatic control subjects 131 
(age 4.75 (1.6-16) years) were either (A) having a bronchoscopy to investigate upper airway 132 
symptoms and agreed to extra research samples being taken or (B) were undergoing general 133 
anaesthesia for cardiac catheterization and agreed to have a research bronchoscopy at the same 134 
time (see Table 1 and online repository (OR) Table E2 for details). The study was approved by the 135 
NRES Committee London - Chelsea, and informed parental consent and child assent were obtained. 136 
In addition to the above mentioned cohort, findings relating to intra-epithelial inflammation were 137 
confirmed in biopsies obtained from a previously published cohort (reference (5)) of children with 138 
STRA (n=21) and controls (n=5). In all figures the latter will appear as grey symbols and their clinical 139 
details are described in detail in the OR and Table E1.  Inclusion of both cohorts of children is of vital 140 
importance to the strength of the findings since we were able to replicate the finding even in this 141 
second cohort. There is no duplication of the data as we merely used the archived biopsy samples to 142 
examine neutrophils, which had not previously been examined in these samples. Further details of 143 
investigations are given in the Methods section in this article’s Online Repository at 144 
www.jacionline.org. 145 
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 146 
Epithelial culture and stimulation 147 
Primary bronchial epithelial cells (PBECs) were seeded into tissue culture flasks containing BEGM and 148 
used at passage 3 for all experiments. PBECs were stimulated with recombinant human IL-17A 149 
(eBioscience, San Diego, CA) and IL-22 (eBioscience) alone, or to cells pre-treated with Budesonide 150 
(Breath Limited, UK) as stated in (24). Culture supernatants were collected after 24h and samples for 151 
mRNA extraction were harvested after 8h stimulation (see OR). 152 
 153 
Quantification of cytokines 154 
Cell culture supernatant was collected and cytokines analysed using ELISA and Milliplex human 155 
cytokine panel I and II (see OR).   156 
 157 
Cytomix 158 
BAL cytokine quantification was performed using Flowcytomix
TM
 Human TH1/TH2/TH9/TH17/Th22 159 
13 plex multiplex (eBioscience, San Diego, CA) (OR).  160 
 161 
Flow cytometry 162 
Lymphocytes used for compensations and fluorescence minus one (FMOs) were extracted from 163 
peripheral blood and cells from the airway lumen were obtained after centrifuge of broncho-alveolar 164 
lavage fluid. Cells were stained for extracellular markers CD3, CD4, CD8, CD161, γδTCR and 165 
intracellular IL-17A (eBiosciences, mouse anti-human 5µl per well) (OR). 166 
 167 
RNA extraction and real-time PCR 168 
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Total RNA was extracted from epithelial cells using the Qiagen RNeasy Mini Kit (Qiagen, Hilden, 169 
Germany). cDNA was synthesized from 500ng of total RNA and analysed by using High Capacity 170 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster city, CA) (OR).  171 
 172 
Histopathology 173 
Endobronchial biopsies were processed to paraffin. Five-micrometre sections were stained with 174 
haematoxylin and eosin and used to assess morphology and consecutive sections were used for 175 
Masson’s trichrome (Sigma Aldrich) for collagen staining, Congo red for staining of eosinophils and 176 
immunohistochemical staining for IL-17A, IL-17RA and neutrophil elastase (OR).  177 
 178 
Statistical analysis 179 
Sample size was opportunistic since there are no data to inform a power calculation. Nonparametric 180 
tests including Mann-Whitney U test and Kruskal Wallis test with Bonferroni post hoc test were used 181 
to detect differences between 2 groups or more than 2 groups, respectively using GraphPad Prism 6 182 
(GraphPad Software, La Jolla, CA). Correlations were assessed using the Spearman rank correlation 183 
test. P<0.05 was considered significant.  184 
  185 
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RESULTS 186 
Patient demographics  187 
Clinical characteristics are shown in Table 1. BAL bacterial culture was positive in 9/51 (15.6%) and 188 
BAL viral PCR was positive in 5/51 (9.8%) of STRA patients. There was a parental report of exposure 189 
to tobacco smoke in 15/41 (37%) STRA patients which was confirmed using urinary cotinine levels.  190 
 191 
A subgroup of STRA is characterised by increased intra-epithelial neutrophils 192 
Previous findings from our group (5) which showed increased BAL and submucosal eosinophils in 193 
children with STRA compared to controls were confirmed in the present study (Figure 1A-B and D-E). 194 
However, when investigating intra-epithelial eosinophils in both the present and the previous cohort 195 
(5) we found no eosinophils in the epithelium of controls or children with STRA (Figure 1C and F). 196 
Since severe asthma in adult patients (13) and in murine models (10, 25-27) has been associated 197 
with neutrophilia, we quantified the number of neutrophils in the submucosa and epithelium in 198 
endobronchial biopsies from children with STRA and controls. In keeping with our previous findings 199 
(5), neutrophil counts were not increased in the submucosa of children with STRA compared to 200 
controls (p=0.9, Figure 1G-H and J-K). However, intra-epithelial neutrophils, expressed both as 201 
proportion of all neutrophils in the biopsy as well as neutrophils per length basement membrane, 202 
were significantly higher in children with STRA compared to controls (p=0.01 and 0.007, respectively) 203 
(Figure 1I and L). We also confirmed the increase in intra-epithelial neutrophils in STRA in biopsies 204 
obtained from a previous cohort (5) of children with STRA (Figure 1I, shown as grey symbols; See 205 
Table E1 OR for clinical details of these patients). The patients with intra-epithelial neutrophils 206 
(referred to as Neutrophil
high
) had (median (range)) 0.02 (0.004-0.04) neutrophils per length of RBM 207 
compared to the Neutrophil
low
 (0 (0-0)) (p=0.007). There was no difference in number of intra-208 
epithelial neutrophils between STRA patients treated with maintenance oral and inhaled steroids 209 
compared to those treated with only inhaled steroids (p=0.8). 210 
 211 
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Children with STRA did not have increased BAL or tissue IL-17A 212 
To investigate any relationship between neutrophils and airway IL-17A in STRA, endobronchial 213 
biopsies were stained for IL-17A. IL-17A expression was observed in small mononuclear cells as well 214 
as in a larger mononuclear cell population in the adventitia of the bronchial wall, but there was no 215 
difference in number of IL-17A positive cells between controls and patients with STRA (Figure 2A-B). 216 
No IL-17A expression was seen within the epithelium (Figure 2A and C). Although undetectable in 217 
most samples, IL-17A levels in BAL were similar in children with STRA and controls (Figure 2D). IL-22 218 
was detected in BAL fluid in 15 of 25 controls (60%) and 25 of 37 STRA patients (68%). However, IL-219 
22 levels were similar in both groups (Figure 2E). There was also no difference in the proportion of 220 
Th17 (CD4
+
IL-17
+
) (Figure 2F) or IL-17
+
 γδT cells (Figure 2G) in BAL from children with STRA compared 221 
to controls.  222 
 223 
Children with STRA had increased submucosal and epithelial expression of IL-17RA  224 
We further wanted to investigate the tissue expression of the receptor for IL-17A. IL-17RA was 225 
expressed in small mononuclear and polymorphonuclear cells in the submucosa in controls (Figure 226 
3A) and patients with STRA (Figure 3B). Strong expression was also present in the epithelium of 227 
patients with STRA (Figure 3B). There was significantly increased expression of IL-17RA in both 228 
submucosa (Figure 3C) and epithelium (Figure 3D) expressed as positive pixels per area (positivity) in 229 
STRA compared to controls. Epithelial IL-17R expression remained elevated in STRA even after 230 
excluding the patients with a positive bacterial culture or viral detection (p=0.006). There was no 231 
difference in IL-17RA expression between the patients taking maintenance oral steroids and inhaled 232 
steroids compared to those only on inhaled steroids (p=0.3). 233 
Since intra-epithelial IL-17R expression was significantly increased in STRA, we determined how the 234 
bronchial epithelium responds to stimulation with IL-17A alone or in combination with Budesonide. 235 
mRNA expression of IL-17RA and C was comparable between STRA and controls at baseline, but 236 
expression was significantly increased in STRA compared to controls following IL-17A stimulation 237 
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alone, and with the addition of Budesonide to cultures (Figure 3E and F). Furthermore, better 238 
symptom control, measured using the asthma control test (ACT), correlated with increased IL-17RA 239 
expression in the epithelial compartment in children with STRA (Figure 3G).  240 
 241 
IL-17A stimulation of bronchial epithelial cells from STRA children induced IL-8 secretion   242 
Since IL-8 is a neutrophil chemo-attractant and we had seen increased intra-epithelial neutrophils in 243 
STRA, levels of IL-8 were measured in BAL fluid. IL-6 was measured as a comparative marker of a 244 
general inflammatory response. BAL IL-8 and IL-6 levels were similar in STRA and controls (Figure 4A-245 
B). This was unchanged after patients with a positive BAL bacterial culture or viral detection were 246 
excluded. IL-17A has previously been shown to induce IL-8 from bronchial epithelial cells (28). In 247 
order to investigate the relationship between IL-17A, epithelial cells and neutrophils we measured 248 
IL-8 secretion from PBEC culture supernatants following IL-17A and IL-22 stimulation, with or 249 
without Budesonide. Primary bronchial epithelial cells from patients with STRA secreted significantly 250 
higher amounts of IL-8 compared to cells from control patients. This effect was observed following 251 
stimulation with IL-17A alone, in combination with IL-22, or with IL-22 alone (Figure 4C). Importantly, 252 
IL-8 secretion was unaffected by the presence of Budesonide (Figure 4C). In contrast, levels of 253 
epithelial IL-6 secretion were comparable between STRA patients and controls (Figure 4D).  Levels of 254 
interleukin (IL) -13 (Th2 cytokine), and interferon (IFN)-γ (Th1 cytokine) in epithelial cell culture 255 
supernatants were similar between STRA and controls. However, levels of the neutrophil 256 
chemoattractant GRO was increased in STRA compared to controls upon IL-17A stimulation (Figure 257 
E1 (OR).    258 
 259 
To further investigate the link between increased IL-17A receptor expression, intra-epithelial 260 
neutrophils and a clinical phenotype, correlations with clinical parameters were performed. We 261 
found no correlations with any confounding factor such as age or BMI in STRA children. Neither was 262 
there any association between intra-epithelial neutrophils and parental smoking status or BAL 263 
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bacteriology/virology (Table 2). Tissue expression of IL-17A and IL-17RA was also compared in 264 
patients with and without intra-epithelial neutrophils. Although no significant differences were 265 
found, there was a trend for increased epithelial IL-17RA expression in the group with intra-epithelial 266 
neutrophils (Figure E3 OR). Two subpopulations of children with STRA were apparent based on the 267 
presence or absence of intra-epithelial neutrophils. Patients were therefore divided into an intra-268 
epithelial Neutrophil
high
 and Neutrophil
low
 group. There were no differences in the number of 269 
submucosal, epithelial or BAL eosinophils (Figure 4E and F), total IgE (Figure 4G) or exhaled nitric 270 
oxide (FeNO) (Figure 4H) between the Neutrophil
high
 and Neutrophil
low
 group. There was no 271 
relationship between reticular basement membrane thickness, a marker of airway remodelling, and 272 
intra-epithelial neutrophils (Fig E5E). However, the Neutrophil
high
 STRA patients had a significantly 273 
higher ACT score (Figure 4I) and were prescribed lower dose maintenance inhaled corticosteroids 274 
compared to the Neutrophil
low
 STRA patients. FEV1 %predicted (Figure 4K) was significantly higher in 275 
the Neutrophil
high
 STRA patients, and the proportion of intra-epithelial neutrophils positively 276 
correlated with FEV1 %predicted (Figure 4L).  277 
  278 
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DISCUSSION 279 
We have shown that a sub-group of children with STRA have increased intra-epithelial neutrophils 280 
compared to younger non-asthmatic controls, which surprisingly and contrary to our hypothesis, 281 
was associated with better FEV1 %predicted, symptom score and lower maintenance inhaled 282 
steroids. In contrast, there were no intra-epithelial eosinophils apparent in STRA. Although there 283 
was no difference in tissue or luminal IL-17A, paediatric STRA patients exhibited increased 284 
submucosal and epithelial expression of IL-17R. Collectively our data indicates a potential beneficial 285 
role for intra-epithelial neutrophils in this sub-phenotype of asthma.  286 
The association between intra-epithelial neutrophils and higher FEV1, higher ACT score and less 287 
inhaled corticosteroid treatment suggests neutrophils specifically within the epithelium may have a 288 
protective role in this asthma phenotype. Most previous studies were in adult asthma patients and 289 
very few (including ourselves) have looked at the specific localisation of neutrophils within the 290 
airway (6, 7, 29). Having found a relationship between intra-epithelial neutrophils and lung function 291 
in the children reported here, we retrospectively quantified epithelial neutrophils in archived 292 
biopsies from our previously published cohort (5). The biopsies from the older cohort had not 293 
previously been assessed for intra-epithelial neutrophils and confirmed an association between 294 
intra-epithelial neutrophils and better spirometry, a significant strength of the study. Unlike intra-295 
epithelial neutrophils, eosinophils were not present within the epithelium of children with STRA. 296 
However, the increased eosinophils in the submucosa and lumen that we have reported previously 297 
(5), were confirmed here (Figure 1A&B).  Although we cannot confirm a direct functional role of 298 
neutrophils in paediatric STRA, the localisation of these cells within the epithelium may point to a 299 
specific role in host defence in this phenotype. Adult data suggest there may be at least two 300 
phenotypes associated with airway neutrophilia; beneficial as a response to infections, or harmful 301 
potentially driven by environmental irritants such as tobacco smoke (30). Exposure to viruses, 302 
bacterial endotoxins and air pollution are common triggers of a neutrophil-rich inflammation and 303 
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consequently could lead to asthma symptoms. Other studies have shown increased numbers of 304 
intra-epithelial neutrophils in various bacterial, viral and fungal infections as well as in cystic fibrosis 305 
and COPD (31-35). However, we found no association between intra-epithelial neutrophils and BAL 306 
bacteriology/virology or parental smoking status. Only 1% of bacteria can be cultured (36), therefore 307 
we cannot rule out that the children had other infections or an altered microbiota that we could not 308 
detect (37). It is also important to highlight that the children in this study were clinically stable and 309 
had at least 2 weeks since any exacerbation at the time of bronchoscopy. Since neutrophils have a 310 
high turnover and short lifespan it is likely that the neutrophils observed within the epithelium in 311 
these patients are inherently present as opposed to recruited in response to an insult during an 312 
exacerbation.  313 
There is an increasing need to find biomarkers that will indicate sub-groups of patients (Th2-low, 314 
neutrophil-high) to enable effective personalised therapies. Other studies have identified that BAL 315 
and sputum neutrophils are more abundant in severe asthmatics (38) (7). In a study investigating the 316 
molecular phenotype of severe asthma in children, both neutrophils and eosinophils were found to 317 
be elevated in BAL fluid from children with severe asthma compared to adult controls (39). These 318 
children also had high levels of GRO and IL-8 in BAL fluid (39). However, the specific location of 319 
neutrophils in the sub compartments of the bronchial wall was not investigated. The neutrophils in 320 
our study are intra-epithelial and hence unlikely to result in a predictive biomarker in the periphery 321 
or airway lumen. However, molecules that represent intra-epithelial neutrophils could be 322 
investigated in induced sputum in future studies. Unfortunately we were unable to collect sputum 323 
from enough patients with intra-epithelial neutrophils to undertake such an analysis.  324 
It is possible that the intra-epithelial neutrophils might be migrating through the epithelium into the 325 
lumen (33-35). But the increased epithelial expression of IL-17R, as well as the increased local 326 
epithelial production of neutrophil chemoattractants including IL-8 and GRO that we have 327 
demonstrated suggest that neutrophils are trapped in the epithelial layer in children with STRA. 328 
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Although speculative and further investigation is warranted, this might indicate an epithelial 329 
microenvironment that is dependent on altered expression of epithelial adhesion molecules that 330 
results in trapping of neutrophils in the epithelial layer (36, 37). 331 
There is scant information regarding the role of IL-17A in paediatric STRA. Higher numbers of IL-17A 332 
positive cells have been found in the bronchial submucosa from adults with severe asthma 333 
compared to controls (8). IL-17 mRNA and numbers of IL-17 positive lymphocytes are also increased 334 
in BAL from asthmatic patients (10, 11, 40). A recent study that has investigated the Th17 high 335 
phenotype in adult asthma has shown that a Th17 high signature is associated with steroid 336 
dependent moderate to severe asthma and eosinophilia (41). But despite this signature there were 337 
no significant differences in lung function between patients. In addition, when IL-17 was blocked in a 338 
murine model of HDM induced allergic airways disease, there was no impact on lung function, 339 
eosinophils or neutrophils (41). Other studies have shown that Th17 mediated airway inflammation 340 
is steroid resistant(42). Furthermore, Nanzer et al., reported PBMCs from adult severe asthmatics 341 
exhibited increased levels of Th17 cytokines, which were not inhibited by steroids (43). 342 
 We were careful to ensure all reagents were IL-17A specific, eliminating effects of contamination 343 
with IL-17F. Although significantly higher serum levels of IL-17A have been reported in children with 344 
asthma exposed to diesel exhaust particles (44) we found no increase in IL-17A in BAL fluid. 345 
Importantly, IL-17A levels were detectable, but similar between STRA and controls, suggesting little 346 
influence from dilution effects of BAL.  However, this might be because samples were collected 347 
during stable disease rather than following challenge or during disease exacerbation. After 348 
performing a double stain with IL-17A and the major leukocyte populations we found that the major 349 
cell types in the submucosa expressing IL-17A were CD3+ lymphocytes and neutrophils. However, 350 
neither the epithelial cells nor infiltrating leukocytes within the epithelium were IL-17A positive. In 351 
contrast, our patients with STRA did show enhanced IL-17RA immunoreactivity in submucosa and 352 
epithelium as well as increased mRNA expression of IL-17RA and C upon stimulation of PBECs with 353 
IL-17A when compared to non-asthmatic controls. IL-17A and IL-17F both signal through IL-17RA 354 
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(25), and have fundamental roles as neutrophil chemoattractants (26, 33). However, we found no 355 
association between neutrophils or IL-17A levels and infection in our patients, albeit molecular 356 
microbiological techniques were not used.   357 
Deficiency in IL-17RA results in impaired neutrophil responses to allergens in mouse models (45, 46). 358 
Elevation of IL-17RA and C suggests a role in neutrophil migration, either via a direct response to IL-359 
17A or via effector molecules such as IL-8. Although no significant difference was found between the 360 
STRA patients with or without intra-epithelial neutrophils with regard to IL-17A and IL-17RA 361 
expression in submucosa or epithelium, there was an indication of higher epithelial IL-17RA 362 
expression in the Neutrophil
high
 patients. We found no increased production of IL-6 in our study, 363 
which indicates a specific IL-17A driven epithelial response, characterised by the neutrophil 364 
chemoattractants IL-8 and GRO which were significantly increased with IL-17A stimulation of PBECs 365 
from STRA compared to controls. These findings question the rationale for treating children with 366 
STRA with anti-IL-17A antibody. A monoclonal antibody against IL-17RA, Brodalumab, has shown no 367 
benefit in adult patients with moderate-to-severe asthma (47) and our data suggests its use in 368 
children with STRA is unlikely to be beneficial. 369 
All of the STRA patients in our manuscript were symptomatic and had poor control despite a high 370 
dose of inhaled steroids. Corticosteroids have been shown to increase airway neutrophils in asthma 371 
(48, 49) and molecules that are associated with suppression of neutrophil apoptosis are upregulated 372 
by glucocorticosteroids. This may be an unwanted effect of asthma therapy. In contrast, our data 373 
indicate patients with lower epithelial neutrophils were prescribed higher doses of maintenance 374 
inhaled steroids, suggesting an altered relationship between intra-epithelial neutrophils and 375 
glucocorticosteroids. This suggests the neutrophil low group may be less sensitive to steroids, since 376 
they were on a higher median dose as a group.  377 
We have shown an association between increased IL-17RA expression and STRA. IL-17A induced 378 
epithelial secretion of IL-8 was also unaffected by the presence of Budesonide.  Previous studies 379 
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have also shown a lack of effect of dexamethasone on IL-17A production from PBMCs in both mice 380 
and humans (27, 43). These data suggest a lack of association between IL-17A and steroids in 381 
patients with severe asthma. Interestingly, it has been shown that the release of GRO and IL-8 382 
induced by IL-17 in the bronchial epithelial cell line 16-HBE is sensitive to hydrocortisone treatment 383 
(50). We have found similar results with this immortalised cell line (Figure E4, OR), confirming critical 384 
functional differences between PBECs and 16-HBEs and emphasising the importance of using 385 
primary cells from asthmatic patients.    386 
The strengths of this study include the large number of carefully characterised children with STRA, a 387 
phenotype of asthma that has been little studied, and the comparison of clinical parameters with 388 
morphological studies and functional in vitro assays using primary airway epithelial cells from the 389 
same patients. However, we acknowledge some limitations. We did not include a control group of 390 
mild to moderate asthma, nor did we include true healthy controls. Although an invasive procedure 391 
involving a general anaesthetic cannot be ethically justified for research studies in children, the 392 
controls included did not have lower respiratory symptoms, and when we have used similar patients 393 
previously we have found meaningful group differences (5, 51, 52). In addition, the controls were 394 
younger because isolated upper airway problems are less common in school-aged children.  395 
In conclusion, our study shows that children with STRA compared to younger non-asthmatic controls 396 
have an exaggerated epithelial response to IL-17A, with increased expression of IL-17RA in the 397 
airway submucosa and epithelium. Primary bronchial epithelial cells from children with STRA 398 
responded to IL-17A stimulation with elevated production of the neutrophil attracting mediators IL-8 399 
and GRO compared to controls. Furthermore, increased numbers of neutrophils were found only in 400 
the epithelial compartment in a sub-group of children with STRA and this finding was associated with 401 
better lung function, better symptom control and lower dose maintenance inhaled steroids. The 402 
critical role of the bronchial epithelium and its interactions with airway leukocytes in determining 403 
downstream functional effects has been highlighted. Our study shows that there are two sub-groups 404 
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within the paediatric STRA phenotype: intra-epithelial Neutrophil
high
 and Neutrophil
low
, further 405 
demonstrating that STRA is heterogeneous and requires careful sub-phenotyping to identify optimal 406 
personalised molecular therapies.   407 
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FIGURE LEGENDS 565 
Figure 1. Eosinophils and neutrophils in different lung compartments. Eosinophil percentage in BAL 566 
(A) (controls n=11, STRA n=31), numbers per area of submucosa (B) (non-asthmatic controls n=7, 567 
STRA n=20) and intraepithelial eosinophils per length of RBM (C) (controls n=7, STRA n=20). 568 
Representative micrographs of Congo Red stain for eosinophils in non-asthmatic controls (D) and 569 
STRA (E). (F) Show high magnification picture of epithelium with no eosinophils in STRA. Neutrophil 570 
percentage in BAL (G) (non-asthmatic controls n=12, STRA n=52), numbers per area of submucosa 571 
(H) (non-asthmatic controls n=10, STRA n=28) and proportion of intraepithelial neutrophils (I) (non-572 
asthmatic controls n=13, STRA n=37). Representative micrographs of immunohistochemical stain for 573 
elastase in non-asthmatic controls (J) and STRA (K). (L) Show high magnification picture of 574 
intraepithelial neutrophils in STRA. Scale bar: 200 μm (D, J), 100 μm (E, K), 20 μm (F) and 10 μm (L). 575 
Statistical significance between non-asthmatic controls and STRA was tested using Mann–Whitney 576 
test. 577 
Figure 2. Sources and expression of IL-17A in children with STRA compared to non-asthmatic 578 
controls. Representative micrograph of immunohistochemical stain for IL-17A in STRA (A). Scare bar: 579 
100 μm. Quantification of the number of IL-17A expressing cells per area in submucosa (B) (non-580 
asthmatic controls n=6, STRA n=39) and bronchial epithelium (C) (non-asthmatic controls n=6, STRA 581 
n=32). BAL levels of IL-17A (D) (non-asthmatic controls n=11, STRA n=23) and IL-22 (E) (non-582 
asthmatic controls n=11, STRA n=23) non-asthmatic controls and children with STRA. Percentages of 583 
IL-17A expressing TH17 (F) (non-asthmatic controls n=10, STRA n=13) and gamma delta (G) (non-584 
asthmatic controls n=8, STRA n=11) lymphocytes in children with STRA compared to non-asthmatic 585 
controls. Statistical significance between non-asthmatic controls and STRA was tested using Mann–586 
Whitney test. 587 
Figure 3. Representative micrographs of immunohistochemical stain for IL-17RA in non-asthmatic 588 
controls and STRA patient (A and B, respectively). Scare bar 100 μm (A) and 50 μm (B). 589 
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Quantification of the expression (positive pixels per area) of IL-17RA in submucosa (non-asthmatic 590 
controls n=6, STRA n=31) and epithelium (non-asthmatic controls n=6, STRA n=24) (C, D, 591 
respectively). mRNA expression of IL-17RA and C in PBECs after stimulation with IL-17A and 592 
Budesonide (non-asthmatic controls n=3, STRA n=3) (E and F, respectively). Correlations between 593 
ACT score and IL-17RA expression in epithelium (G) (n=21). Statistical significance between non-594 
asthmatic controls and STRA was tested using Mann–Whitney test and correlation analysis was 595 
performed using Spearman rank test, where p<0.05 was considered significant. 596 
Figure 4. Levels of IL-8 (A) (non-asthmatic controls n=9, STRA) and IL-6 (B) (non-asthmatic controls 597 
n=12, STRA n=23) in BAL. Levels of IL-8 (C) and IL-6 (D) in culture supernatant from PBECs after 598 
stimulation with IL-17A, IL-22 and Budesonide D n=24 (controls n=4, STRA n=7 and non-asthmatic 599 
controls n=4, STRA n=7, respectively). Differences in submucosal eosinophils (E) (Neu
hi
 n=10, Neu
lo
 600 
n=15), BAL eosinophils (F) (Neu
hi
 n=12, Neu
lo
 n=20), total IgE (G) (Neu
hi
 n=10, Neu
lo
 n=21), FeNO (H) 601 
(Neu
hi
 n=11, Neu
lo
 n=18), ACT score (I) (Neu
hi
 n=12, Neu
lo
 n=20), dose of inhaled corticosteroids (J) 602 
(Neu
hi
 n=12, Neu
lo
 n=21) and FEV1 % predicted (K) within the group of children with STRA based on 603 
the presence of intraepithelial neutrophils  (Neu
hi
 n=13, Neu
lo
 n=21). Correlations between FEV1 % 604 
predicted and proportion of intraepithelial neutrophils (L) (n=36). Patients from the cohort 605 
previously published in (5) are shown in grey. Statistical significance between controls and STRA was 606 
tested using Mann–Whitney test and correlation analysis was performed using Spearman rank test, 607 
where p<0.05 was considered significant. 608 
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Table 1. Demographics of STRA and control patients undergoing bronchoscopy. 
 
STRA (n=51) 
Non-asthmatic  controls
Ⱡ
 
(n=15)                           
p-value 
Atopy 45/51(88.2%) 1/15 (6.6%)                   0.005 
Male: Female 30:21 8:7  
Age, years 12.6 (6 -16.3) 4.75 (1.6-16)                 0.005 
Duration of symptoms, years 7 (3.5 - 14.3) 
 
 
Weight (Kg) 41.7 (22.3-99.9) 19.2 (8.9-68)  
Weight z score 0.5 (-3.4 - 3.7) 0.4 (-3.1-3.4)  
Height (cm) 150 (106 -188)    
Height z score 0.02 (-3.9 - 2.88)    
Intubation for asthma 4/51 (7.8%) 
 
 
Total IgE(IU/ml) 419 (20-4867) 46.5 (1-210)                   0.003 
Sum of inhalant sIgE (IU/mL) 7.4 (0-321) 0.54 (0-20) 0.1 
Sum of all sIgE (IU/mL) 11.3 (0-321) 1.1 (0-20) 0.2 
BAL Neutrophils(%)
¶ł
 3.7 (1-21.7) 5.4 (4-9)                          0.35 
BAL Eosinophils (%)** 3 (0.3-23) 2 (0-5)                              0.17 
Blood Eosinophils (%) 7.5 (0-21.4) 3.5 (0.9-9.8)                    0.06 
Blood Neutrophils (%) 51 (6-87) 49 (31-71) 0.4 
ACT score 13 (5-23)   
ACT normal (>19/25) 10/51 (19.6%)   
Baseline FEV1 (litres) 1.75 (0.45 - 3.95)   
Baseline % predicted FEV1* 89.4 (24 - 126)   
Number FEV1 ‘normal’ 
     (>80% predicted) 
31/51 (60.7%)    
Baseline FVC (litres) 2.36 (1.37-5.39)    
Baseline % predicted FVC 99.5 (63 - 133)    
Baseline bronchodilator  
     reversibility (%) 
11.4 (-3 -  66.7)    
Baseline FeNO50 (ppb)
¥
 46.2 (5.4 - 164.8)    
Medications      
Daily dose Inhaled 
ǂ
 
     corticosteroid (mcg/day)  
     Budesonide equivalent 
1400 (500-2000) 0 (0-200)  
Leukotriene receptor  
     antagonist 
46/51 (90.1%) 0  
Systemic corticosteroids 6/51 (11.7%) 0  
     Daily dose (mg/day) 6.25 (2.5 - 20)    
Theophylline 4/51 (7.8%) 0  
Data presented as median (range). 
¶ł
 BAL Neutrophils (<3% is normal). **BAL eosinophils (<3% is 
normal).*FEV
1
: presented as percentage predicted.
 ¥
 FeNO: fractional exhaled nitric oxide measured at 
50L/min.
 ǂ
ICS:  inhaled corticosteroids/day. Ⱡ80% of the non-asthmatic controls symptoms such as stridor 
(tracheal stenosis, laryngotracheomalacia), reflux, dry cough, or haemoptysis. The remaining 20% were 
undergoing general anaesthesia for elective cardiac catheterisation and had agreed to a research 
bronchoscopy. For details of diagnosis in the non-asthmatic controls see OR, Table E2. Differences 
between groups were assessed by Mann-Whitney test where P<0.05 is significant. 
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Table 2. Neutrophil, IL-17A and IL-17RA quantification in relation to BAL bacteriology, 
virology and parental smoking status. 
 
STRA (n=51) 
Non-asthmatic 
control (n=15)                          
p-value 
BAL Bacteriology (positive) 8/51 (15.4%) 1/15 (6.6%)  
BAL Virology (positive) 5/51 (9.8%) 1/15 (6.6%)  
Parental smoking (positive) 15/41 (37%)   
Cotinine levels (ng/ml)
¥
 1.3 (1- 4.8)   
IL-17A (submucosa)* 0.09 (0.03-0.3) 0.03 (0.02-0.07) 0.001 
IL-17RA (submucosa)
#
 20 (0-291) 9 (0-47) 0.4 
IL-17RA (epithelium)
#
 0.2 (0.01-0.5) 0.02 (0.007-0.08) 0.0006 
Neutrophils (submucosa)* 8 (0-202) 8 (0-36) 0.9 
Neutrophils (epithelium), % 0 (0-60) 0 (0-0) 0.04 
Eosinophils (submucosa) 54 (4-263) 8 (0-56) 0.01 
Eosinophils (epithelium), % 0 (0-0) 0 (0-0) >.999 
Comparison of intraepithelial neutrophils in STRA groups based on: 
 Positive Negative  
BAL bacteriology 0 (0-17) 0 (0-60) 0.7 
BAL virology 8 (0-17) 0 (0-60) 0.3 
Parental smoking 0 (0-20) 0 (0-60) 0.9 
Data presented as median (range). 
¥ 
>4.8ng/ml indicates exposure to tobacco smoke and 
>50ng/ml is indicative of active tobacco smoking. *Cells per mm
2
.
 #
Positivity (positive 
pixels per all pixels). Differences between groups were assessed by Mann-Whitney test 
where P<0.05 is significant. 
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MATERIAL AND METHODS 24 
Subjects 25 
Fifty-one school-aged children with STRA who were undergoing a clinically indicated bronchoscopy 26 
were recruited from the Royal Brompton Hospital between 2009 and 2015. Patients remained poorly 27 
controlled despite being prescribed high doses of inhaled steroids (800mcg/day budesonide or 28 
equivalent) and receiving additional long-acting β-agonists, and current or a previous failed trial of 29 
montelukast (Table 1). 12% of the patients with severe asthma were also taking regular oral steroids. 30 
Only children with true STRA were included in the study (1-3). Those with difficult asthma, in whom 31 
underlying modifiable factors such as persistent allergen exposure, poor adherence and/or inhaler 32 
technique that might contribute to poor asthma control were excluded (4). The remaining children 33 
with STRA underwent invasive analysis with bronchoscopy, bronchial brushings, bronchoalveolar 34 
lavage (BAL) and endobronchial biopsies to characterize airway pathology and develop customised 35 
treatment plans. Atopy was defined as 1 or more positive specific IgE RAST (≥0.34 kU/L) or 1 or more 36 
positive skin prick test results to aeroallergens. Asthma control was assessed by using the Asthma 37 
Control Test (ACT) (5, 6); poor control was defined as a score of less than 20 of 25. Spirometry and 38 
bronchodilator reversibility (BDR) defined as a greater than 12% change from baseline FEV1 were 39 
measured according to American Thoracic Society/European Thoracic Society guidelines (7, 8). 40 
Exhaled nitric oxide measurements at a flow rate of 50 mL/s were made with a chemiluminescence 41 
analyzer (NIOX; Aerocrine AB, Solna, Sweden) in accordance with American Thoracic 42 
Society/European Thoracic Society guidelines(9). Clinical details of the children with STRA are shown 43 
in Table 1. 15 non-asthmatic control subjects were either having a bronchoscopy to investigate 44 
upper airway symptoms and agreed to extra research samples being taken or were undergoing 45 
general anaesthesia for cardiac symptoms and agreed to have a research bronchoscopy at the same 46 
time (see Table 1 and Table E2 for details). The study was approved by the Brompton and Harefield 47 
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National Heart and Lung Institute Ethics Committee, and informed parental consent and child assent 48 
were obtained.  49 
Findings relating to epithelial inflammation in this group were confirmed in biopsies already 50 
obtained from a previously published cohort of children with STRA (n=21) and non-asthmatic 51 
controls (n=5) (Table E1 OLS). The inclusion criteria in this cohort were the same as for the patients 52 
described above (see also reference (1). Children aged 5 to 16 years with severe therapy resistant 53 
asthma were included. Definitions of uncontrolled disease and entry criteria were: 54 
1. Persistent (most days for ≥3 months) chronic symptoms (use of short-acting β2-agonists ≥3 times 55 
per week) of airway obstruction despite high doses of inhaled corticosteroids (ICSs; ≥800 μg/d 56 
budesonide equivalent) and/or regular oral corticosteroids, long-acting β2-agonists, and current (or 57 
previous failed trial of) montelukast. 58 
2. Recurrent severe exacerbations requiring 1 or more admission to the intensive care unit or 2 or 59 
more hospital admissions requiring intravenous medications or 2 or more courses of oral 60 
corticosteroids in the past year despite therapy for persistent symptoms as described in above  61 
3. At least 1 very sudden (≤6 hours) severe attack (requiring hospitalization) without warning despite 62 
therapy for persistent symptoms, as described in above. 63 
Evaluations were performed to assess medication, dose, device and technique, atopic status, asthma 64 
understanding and assessment of adherence, environment, and any psychosocial issues were 65 
addressed. After assessment, those classified as true STRA were further investigated. The study was 66 
approved by the local research ethics committee, and all procedures were performed after obtaining 67 
written informed parental consent and, where appropriate, child assent. 68 
 69 
Epithelial cell culture and stimulation 70 
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Epithelial brushings were obtained at bronchoscopy using a fiberoptic bronchoscope (Olympus, 71 
Keymed, UK). A sterile single-sheathed nylon cytology brush was used to sample epithelial cells from 72 
the bronchial mucosa of the second- and third-generation bronchi. Cells were transferred to 5mL 73 
bronchial epithelial growth medium (BEGM, Lonza, Walkerville, MD, USA) and the samples were 74 
centrifuged at 1500rpm× g for 5 min to pellet the cells. Primary cultures were established by 75 
reconstituting the pellet in BEGM and cells were seeded into collagen coated T25 tissue culture 76 
flasks containing 5mL BEGM. Cultures were routinely tested for mycoplasma infection. 77 
Primary paediatric bronchial epithelial cells were grown to 80–90% confluence in 12 well plates. On 78 
the day of stimulation, the growth medium was replaced with bronchial epithelial basal medium 79 
(Lonza) 4h before start of experiment. The primary epithelial cells were used at passage 3 for all 80 
experiments. Primary bronchial epithelial cells were stimulated with recombinant human IL-17A 81 
(eBioscience, San Diego, CA) and IL-22 (eBioscience) at 10ng/mL alone, or with added budesonide at 82 
a final concentration of 10
−8
 mol/L. All experiments were done in triplicates. After 24h cell culture 83 
supernatants were taken, and cell lysates were prepared in RIPA buffer containing protease inhibitor 84 
tablets (Roche Diagnostics, Mannheim, Germany). Samples for mRNA extraction were undertaken in 85 
separate 12-well plates and cells were harvested in Trizol (Sigma, St Louis, MO) after 8h stimulation. 86 
16HBEs, a differentiated SV-40 transformed bronchial epithelial cell line, was used in the same way 87 
as the primary HBECS and stimulated as described above with IL-17, IL-22, IL-17 and IL-22 in 88 
combination with or without Budesonide.   89 
 90 
Quantification of cytokines 91 
Cell culture supernatant was collected and cytokines were analysed using ELISA and Milliplex. 92 
Milliplex human cytokine panel I and II (HCYP2MAG-62K and MPXHCYTO-60K, Millipore Corporation, 93 
Billerica, MA) were used to detect levels of IL-4, -5, -6, -8, -9, -10, -13, -17, IP-10, MCP-1, MDC, 94 
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RANTES, TNF-α, VEGF, Eotaxin, Eotaxin-2, Eotaxin-3, FGF-2, GRO, IFN-γ, TARC, SCF, TSLP and IL-33 95 
according to manufacturer’s instructions. Levels of IL-6 and IL-8 were confirmed with standardized 96 
sandwich ELISAs, according to the manufacturer's protocol (88-8086 and 88-7066, eBiosciences).   97 
 98 
Cytomix 99 
BALF cytokine quantification was performed using Flowcytomix
TM
 Human TH1/TH2/TH9/TH17/Th22 100 
13 plex multiplex (eBioscience, San Diego, CA) to detect levels of IFN-γ, IL-1ß, IL-2, IL-4, IL-5, IL-6, IL-101 
9, IL-10, IL-12 (p70), IL-13, IL-17A, IL-22, and TNF-α according to manufacturer’s instructions. 102 
Samples were assayed using the BD Fortessa flow cytometer. Data analysis was performed using 103 
Flowcytomix
TM
 software (eBioscience, San Diego, CA) and GraphPad Prism (V.6 for Mac OS X, 104 
GraphPad Software Inc). 105 
 106 
FACS 107 
Lymphocyte used for compensations and fluorescence minus one (FMOs) were extracted from 108 
peripheral blood using a density gradient medium (LymphoprepTM) cell concentration was 109 
optimized to 2-4 x 105 cells per 100l. Cells from the airway lumen were obtained after centrifuge of 110 
broncho-alveolar lavage fluid to obtain a cell pellet. Cells were re-suspended in RPMI complete and 111 
plated at 2-4 x 105 cells per 100l. Cells were stimulated for 4 hours with phorbol 12-myristate 13-112 
acetate (PMA), Ionomycin and Brefeldin A. Cells were stained for extracellular markers CD3 113 
(1:50),CD4 (1:50),CD8, CD161, γδTCR and intracellular staining for IL-17A (eBiosciences, mouse anti-114 
human 5µl per well).  115 
Samples were assayed using the BDFortessa flow cytometer (BD, UK). Data were analysed using 116 
FlowJo (V.9.2, TreeStar Inc) and GraphPad Prism (V.6 for Mac OS X, GraphPad Software Inc). 117 
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 118 
RNA extraction and real-time PCR 119 
Total RNA was extracted from epithelial cells by using the Qiagen RNeasy Mini Kit (Qiagen, Hilden, 120 
Germany). cDNA was synthesized from 500ng of total RNA and analysed by using High Capacity 121 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster city, CA). Reactions were run with 122 
TaqMan primers against IL-17RA, IL-17RC, Fibronectin, Collagen I (Applied Biosystems) and TaqMan 123 
Fast Advanced Master Mix (Applied Biosystems) according to manufacturer’s directions on a Viaa-7 124 
(Life Technologies) instrument and gene expression was analysed using the change-in-threshold 125 
ΔΔCt- method. 126 
 127 
Histopathology 128 
Endobronchial biopsies were processed to paraffin. Five-micrometre sections were stained with 129 
haematoxylin and eosin and used to assess morphology and consecutive sections were used for 130 
Masson’s trichrome staining (Sigma Aldrich) and immunohistochemical staining for IL-17A, IL-17RA 131 
and neutrophil elastase. Human polyclonal goat anti–IL-17 antibody (R&D, Rocky Hill, NJ; dilution 132 
1:50) and human monoclonal mouse anti–IL-17RA antibody (R&D, Rocky Hill, NJ; dilution 1:50) was 133 
detected by using Dako EnVision (K5007) or anti-goat HRP (Dako). Staining was visualised with 3’,3’-134 
diaminobenzidine (DAB kit, Vector Laboratories, Peterborough, UK) and counterstained with 135 
haematoxylin. Human monoclonal mouse anti-elastase (Dako, Glostrup, Denmark, dilution 1:100) 136 
was used for detection of neutrophils. Primary was detected with Vector Laboratories ABC kit 137 
(AK5000) according to manufacturer’s instructions and was visualised with Fast Red and counter 138 
stained with haematoxylin. IL-17A positive cells were quantified in the submucosa and expressed as 139 
cells per square millimetre of tissue using ImageScope (Aperio, Vista, CA). IL-17RA was quantified 140 
using ImageScope positive pixel count algorithm in the submucosa and epithelium and expressed as 141 
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positive pixels divided by total number of pixels (positivity). Neutrophil density was quantified in the 142 
epithelium and the subepithelial compartment using ImageScope. Neutrophils in the submucosa 143 
were expressed as cells per square millimetre tissue and intraepithelial neutrophils as the proportion 144 
of intraepithelial neutrophils of all neutrophils present in the biopsy as well as number of cells per 145 
micrometre reticular basal membrane length. Since only a proportion of patients with STRA had 146 
intraepithelial neutrophils we included biopsies from another cohort with similar patients (patient 147 
details have been previously published (1)) to be able to do a statistically assured comparison and 148 
correlation to FEV1 % predicted.     149 
Double staining with immunofluorescence was used to simultaneously visualise IL-17A together with 150 
the following molecules: CD68 (1:200, Dako, Glostrup, Denmark), elastase (1:200, Dako), tryptase 151 
(Dako) and CD3 (1:50, Dako). The markers were selected to represent multiple leukocyte populations 152 
that might express IL-17A. After antigen retrieval (citrate buffer, pH 6), sections were stained for IL-153 
17A using specific and validated primary antibody (IL-17A, R&D systems) and visualised by an Alexa-154 
Flour 555-conjugated secondary antibody (Molecular Probes, Oregon, USA).  Next, antibodies 155 
against CD68, elastase, tryptase or CD3 were added and visualised using a AlexaF-488 conjugated 156 
secondary antibody. Sections were mounted with Prolong gold mounting medium with DAPI 157 
(Molecular Probes) for visualisation of cell nuclei.  158 
 159 
Statistical analysis 160 
Nonparametric tests Mann-Whitney U tests and Kruskal Wallis test with Bonferroni post hoc test 161 
were used to detect differences between 2 groups or more than 2 groups, respectively, by using 162 
GraphPad Prism 6 software (GraphPad Software, La Jolla, CA). Correlations were assessed by using 163 
the Spearman rank correlation test. Results were considered significant at a p-value < 0.05.  164 
 165 
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RESULTS 166 
 167 
Stimulation of bronchial epithelial cells with IL-17A induced secretion of GRO in children with STRA 168 
Since IL-17A is associated with increased numbers of neutrophils in adult asthma, levels of GRO were 169 
measured in BAL fluid as well as in PBEC culture supernatants following IL-17A and IL-22 stimulation, 170 
with or without Budesonide. Epithelial GRO secretion from bronchial epithelial cells was significantly 171 
increased in patients with STRA compared to non-asthmatic controls with IL-17A stimulation in 172 
combination with budesonide (Figure E1A). No effect was seen with IL-22 stimulation alone.  173 
Detectable levels of IL-6, -8, -13, IP-10, MCP-1, MDC, FGF-2, IFN-γ were also found in cell culture 174 
supernatants using Milliplex but no difference was found between STRA and non-asthmatic controls 175 
expect for IL-8 which confirmed the ELISA data (Figure E2B). The other mediators in the Milliplex kit 176 
were below detection level. 177 
 178 
Correlations between specific serum IgE levels and clinical parameters, neutrophil numbers and IL-179 
17A/RA expression 180 
We did not find any correlation of submucosal or intraepithelial neutrophils, IL-17A and IL-17RA 181 
expression to sIgE levels to any specific allergen nor to the sum of inhaled allergen or to the total 182 
sum of sIgE to all allergens. However, positive correlations were found between sum of sIgE to 183 
inhaled allergens and RBM thickness (rs=0.43, p=0.05) and sum of sIgE to inhaled allergens and 184 
submucosal eosinophils (rs=0.63, p=0.03).  185 
 186 
16-HBEs cell line appears to be sensitive to treatment with Budesonide 187 
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In contrast to the primary HBECs, the 16HBE cell line did not respond with increased IL-6 and -8 188 
production upon stimulation with IL-17A, IL-22 or in combination. However, they did display 189 
sensitivity to Budesonide and showed decreased production of IL-6 and IL-8 upon treatment with 190 
Budesonide (Figure E3A and B). 191 
IL-17A stimulation induced epithelial expression of remodelling mediators  192 
Increased reticular basement membrane (RBM) thickness and airway smooth muscle mass is a 193 
distinct feature of children with STRA (1). Since IL-17A and IL-22 has been associated with airway 194 
remodelling (10-12) we measured epithelial secretion of remodelling mediators in response to 195 
stimulation with these cytokines. VEGF was significantly increased in STRA compared to non-196 
asthmatic controls when IL-17A and IL-22 were used in combination (Figure E5A, p=0.04). 197 
Fibronectin mRNA was increased in STRA compared to non-asthmatic controls when cells were 198 
stimulated with IL-17A alone (p=0.02, Figure E5B), while collagen I was increased in STRA compared 199 
to non-asthmatic controls when cells were stimulated with either IL-22 (p=0.02), IL-17 (p=0.005) or 200 
IL-17 with Budesonide (p=0.05) (Figure E5C). We confirmed our previous findings (1) that children 201 
with STRA have increased RBM thickness (p=0.03, Figure E5E). However, no significant difference in 202 
submucosal collagen deposition was found in bronchial biopsies from non-asthmatic controls and 203 
patients with STRA (p=0.09, Figure E3F and G).     204 
  205 
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FIGURE LEGENDS 206 
Figure E1. Measurement of GRO (A) in culture supernatants from PBECs after stimulation with IL-207 
17A, IL-22 and budesonide (A) (non-asthmatic controls n=4, STRA n=4). Statistical significance 208 
between non-asthmatic controls and STRA was tested using Mann–Whitney test, where p<0.05 was 209 
considered significant. 210 
Figure E2. Tissue density of IL-17A in submucosa (A), IL-17RA in submucosa (B) and IL-17RA in 211 
epithelium (C) in bronchial biopsies from children with STRA divided into Neutrophil
high
 vs. 
low
 groups. 212 
Statistical significance was tested using Mann–Whitney test, where p<0.05 was considered 213 
significant. 214 
Figure E3. Measurement of IL-6 (A), IL-8 (B), IL-13 (C), IP-10 (D), MCP-1 (E), MDC (F), FGF-2 (G),and 215 
IFN-γ (H) in culture supernatants from PBECs after stimulation with IL-17A, IL-22 and budesonide 216 
(non-asthmatic controls n=4, STRA n=4) using Milliplex assay. Statistical significance between non-217 
asthmatic controls and STRA was tested using Mann–Whitney test, where p<0.05 was considered 218 
significant. 219 
Figure E4. Measurement of IL-6 (A) and IL-8 (B) in culture supernatants from 16HBEs after 220 
stimulation with IL-17A, IL-22 and budesonide using ELISA. 221 
Figure E5. The effect of IL-17A on airway remodelling parameters. Measurement of VEGF in culture 222 
supernatants from PBECs after stimulation with IL-17A, IL-22 and Budesonide (A) (non-asthmatic 223 
controls n=4, STRA n=4). mRNA expression  in PBECs after stimulation with IL-17A, IL-22 and 224 
Budesonide of fibronectin (B) and collagen I (C) (non-asthmatic controls n=3, STRA n=3). RBM 225 
thickness in non-asthmatic controls compared to STRA (D) (non-asthmatic controls n=7, STRA n=21) 226 
and RBM thickness within the STRA group when divided into Neutrophil 
high
 vs. 
low
 subgroups (E). 227 
Representative micrographs of bronchial biopsies stained with Masson’s trichrome staining for 228 
collagen (blue) (F control and G STRA). Subepithelial collagen deposition (H) (non-asthmatic controls 229 
n=7, STRA n=9) in bronchial biopsies from non-asthmatic controls and children with STRA expressed 230 
as positive pixels per area. Statistical significance between non-asthmatic controls and STRA was 231 
tested using Mann–Whitney test, where p<0.05 was considered significant.  232 
Figure E6. Immunohistochemical double staining of bronchial biopsies of IL-17A (red – AlexaF 555) 233 
and elastase (A) or CD3 (B) (green – AlexaF 488). Corresponding isotype controls are shown in C-D). 234 
Nuclei are stained blue with DAPI. Scale bar: 100 um.  235 
  236 
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 273 
Table E1. Demographics of STRA and control patients undergoing bronchoscopy in validation 
cohort collected between 2007-2009. 
 
STRA (n=21) Healthy control (n=5)                          p-value 
Atopy 21/21(100%) 0/5 (0%)                    
Male: Female 14:7 3:2  
Age, years 11.2 (8 -16) 11.2 (9 -16)                 0.80 
Weight (Kg) 42.4 (24.1-74.0) 44.7 (37.8-60.2) 0.96 
Height (cm) 141 (114 -159) 160 (144-168) 0.054 
Total IgE(IU/ml) 415 (16-18645) -  
BAL Neutrophils(%)
¶ł
 3 (0-19)                         1.3 (0-14) 0.22 
BAL Eosinophils (%)** 3 (0-51) 0 (0-10)                              0.33 
ACT score
#
 11 (6-22)  -  
Baseline % predicted FEV1* 69 (29 - 98)  98 (78- 106) 0.0072 
Number FEV1 ‘normal’ 
     (>80% predicted) 
6/21 (28.6%)  4/5 (80%)  
Baseline % predicted FVC 99.5 (63 - 133)  93 (89-116) 0.56 
Baseline bronchodilator  
     reversibility (%) 
13.3 (-2 - 135)  -  
Medications      
Daily dose Inhaled 
ǂ
 
     corticosteroid (mcg/day)  
     Budesonide equivalent 
1600 (800-3200) 0  
Systemic corticosteroids 12/21 (57%) 0  
     Daily dose (mg/day) 6.88 (5 - 40) 0  
Data presented as median (range). 
¶ł
 BAL Neutrophils (<3% is normal). **BAL eosinophils (<3% 
is normal).
 #
Asthma control test (>19 is normal).
 
*FEV
1
: presented as percentage predicted.
 
ǂICS: inhaled corticosteroids/day. Differences between groups were assessed by Mann-
Whitney test where P<0.05 is significant. 
 274 
Table E2. Clinical diagnosis and reason for bronchoscopy of non-
asthmatic controls. 
 
Non-asthmatic controls (n=15) 
Elective cardiac catheter 2 
Unexplained hypoxia 1 
Reflux 2 
Tracheal stenosis 2 
Chronic dry cough  5 
Haemoptysis  2 
Laryngotracheomalacia 1 
Data presented as number of patients. 
 275 
